AZ gets US and Canadian rights to Actavis' branded respiratory portfolio
AstraZeneca PLC will pay $600mm up front, plus low-single-digit royalties, to acquire rights to Actavis PLC’s branded respiratory drug portfolio in the US and Canada. AZ will also hand over $100mm related to undisclosed contractual consents and approvals pertaining to previous collaborations with Actavis.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.